Literature DB >> 33639969

Substance use and symptoms of mental health disorders: a prospective cohort of patients with severe substance use disorders in Norway.

Christer Frode Aas1,2, Jørn Henrik Vold3,4, Rolf Gjestad5, Svetlana Skurtveit6,7, Aaron Guanliang Lim8, Kristian Varden Gjerde5, Else-Marie Løberg3,5,9, Kjell Arne Johansson3,4, Lars Thore Fadnes3,4.   

Abstract

BACKGROUND: There is high co-occurrence of substance use disorders (SUD) and mental health disorders. We aimed to assess impact of substance use patterns and sociodemographic factors on mental health distress using the ten-item Hopkins Symptom Checklist (SCL-10) over time.
METHODS: Nested prospective cohort study of 707 participants with severe SUD across nine opioid-agonist-therapy outpatient clinics and low-threshold municipality clinics in Norway, during 2017-2020. Descriptive statistics were derived at baseline and reported by means and standard deviation (SD). A linear mixed model analysis was used to assess the impact of substance use patterns and sociodemographic factors on SCL-10 sum score with beta coefficients with 95% confidence intervals (CI).
RESULTS: Mean (SD) SCL-10 score was 2.2 (0.8) at baseline with large variations across patients. We observed more symptoms of mental health disorders among people with frequent use of benzodiazepines (beta 3.6, CI:2.4;4.8), cannabis (1.3, CI:0.2;2.5), opioids (2.7, CI:1.1;4.2), and less symptoms among people using frequent stimulant use (- 2.7, CI:-4.1;-1.4) compared to no or less frequent use. Females (1.8, CI:0.7;3.0) and participants with debt worries (2.2, CI:1.1;3.3) and unstable living conditions (1.7, CI:0.0;3.3) had also higher burden of mental health symptoms. There were large individual variations in SCL-10 score from baseline to follow-up, but no consistent time trends indicating change over time for the whole group. 65% of the cohort had a mean score > 1.85, the standard reference score.
CONCLUSIONS: People with SUD have a considerable burden of mental health symptoms. We found no association between substance use patterns and change in mental health symptoms over time. This could suggest that the differences observed were indicating flattening of effects or self-medication to a larger degree than medication-related decline in mental health. This call for better individualized mental health assessment and patient care.

Entities:  

Keywords:  Mental disorder; Mental health problems; Opioid dependence; Opioid substitution treatment; Psychological distress; Substance abuse; Substance use disorder

Year:  2021        PMID: 33639969      PMCID: PMC7912462          DOI: 10.1186/s13011-021-00354-1

Source DB:  PubMed          Journal:  Subst Abuse Treat Prev Policy        ISSN: 1747-597X


  40 in total

1.  What have population surveys revealed about substance use disorders and their co-morbidity with other mental disorders?

Authors:  W Hall
Journal:  Drug Alcohol Rev       Date:  1996-06

2.  Co-occurrence between mental distress and poly-drug use: a ten year prospective study of patients from substance abuse treatment.

Authors:  Jasmina Burdzovic Andreas; Grethe Lauritzen; Trond Nordfjaern
Journal:  Addict Behav       Date:  2015-05-08       Impact factor: 3.913

3.  The epidemiology of benzodiazepine misuse: A systematic review.

Authors:  Victoria R Votaw; Rachel Geyer; Maya M Rieselbach; R Kathryn McHugh
Journal:  Drug Alcohol Depend       Date:  2019-05-07       Impact factor: 4.492

Review 4.  Psychiatric disease and drug abuse.

Authors:  Karen Santucci
Journal:  Curr Opin Pediatr       Date:  2012-04       Impact factor: 2.856

5.  Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions.

Authors:  Bridget F Grant; Frederick S Stinson; Deborah A Dawson; S Patricia Chou; Mary C Dufour; Wilson Compton; Roger P Pickering; Kenneth Kaplan
Journal:  Arch Gen Psychiatry       Date:  2004-08

Review 6.  The developmental psychopathology of alcohol use and alcohol disorders: research achievements and future directions.

Authors:  Laurie Chassin; Kenneth J Sher; Andrea Hussong; Patrick Curran
Journal:  Dev Psychopathol       Date:  2013-11

7.  The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability.

Authors:  Else-Marie Løberg; Siri Helle; Merethe Nygård; Jan Øystein Berle; Rune A Kroken; Erik Johnsen
Journal:  Front Psychiatry       Date:  2014-11-18       Impact factor: 4.157

8.  The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario.

Authors:  Alexandra M Franklyn; Joseph K Eibl; Graham Gauthier; David Pellegrini; Nancy E Lightfoot; David C Marsh
Journal:  Harm Reduct J       Date:  2017-01-26

Review 9.  Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?

Authors:  Jørgen G Bramness; Øystein Hoel Gundersen; Joar Guterstam; Eline Borger Rognli; Maija Konstenius; Else-Marie Løberg; Sigrid Medhus; Lars Tanum; Johan Franck
Journal:  BMC Psychiatry       Date:  2012-12-05       Impact factor: 3.630

10.  Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017.

Authors:  Jørn Henrik Vold; Christer Aas; Svetlana Skurtveit; Ingvild Odsbu; Fatemeh Chalabianloo; Johan Reutfors; Anne Halmøy; Kjell Arne Johansson; Lars Thore Fadnes
Journal:  BMJ Open       Date:  2020-08-07       Impact factor: 2.692

View more
  3 in total

1.  Folate Status as a Nutritional Indicator among People with Substance Use Disorder; A Prospective Cohort Study in Norway.

Authors:  Mitra Bemanian; Jørn Henrik Vold; Ranadip Chowdhury; Christer Frode Aas; Rolf Gjestad; Kjell Arne Johansson; Lars Thore Fadnes
Journal:  Int J Environ Res Public Health       Date:  2022-05-09       Impact factor: 4.614

2.  Vitamin D status and associations with substance use patterns among people with severe substance use disorders in Western Norway.

Authors:  Mitra Bemanian; Ranadip Chowdhury; Krister Stokke; Christer Frode Aas; Kjell Arne Johansson; Jørn Henrik Vold; Lars Thore Fadnes
Journal:  Sci Rep       Date:  2022-08-11       Impact factor: 4.996

3.  Effect of fruit smoothie supplementation on psychological distress among people with substance use disorders receiving opioid agonist therapy: protocol for a randomised controlled trial (FruktBAR).

Authors:  Lars T Fadnes; Einar Furulund; Karl Trygve Druckrey-Fiskaaen; Tesfaye Madebo; Jørn Henrik Vold; Maria Olsvold; Marianne Cook Pierron; Siv-Elin Leirvåg Carlsen; Rune Blomhoff; Torgeir Gilje Lid
Journal:  BMC Nutr       Date:  2022-09-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.